Boston Scientific Earns FDA Approval for Next Generation of Drug-Eluting Stents

Boston Scientific Corp. has won U.S. regulatory approval for its next generation drug-eluting stents, the company announced.

The company plans to immediately launch its Taxus Express2 Atom Paclitaxel-Eluting Coronary Stent System, the only drug-eluting stent on the U.S. market for use in vessels as small as 2.25 mm in diameter.

Stents are tiny wire-mesh tubes that are inserted into diseased arteries to prop them open after they have been surgically cleared of blockages.

The use of stents has decreased in recent years amid concerns that the devices could lead to late stent thrombosis, a small but deadly risk of blood clots forming inside the stent a year or more after implantation.

No related posts.